Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | POLA1 | P09884 | 1/20 | 0.68 |
| ▸ | POLD1 | P28340 | 1/20 | 0.68 |
| ▸ | TK1 | P04183 | 6/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | DTYMK | P23919 | 2/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586988 | 1.00 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL3031874 | 1.00 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL18855348 | 1.00 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL77582 | 1.00 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL154177 | 0.98 | POLB (0.65) | POLBPOLA1POLD1TK1BCHE | |
| Triphosphate SCHEMBL27892350 | 0.95 | POLB (0.61) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL28961478 | 0.94 | POLB (0.61) | POLBPOLA1POLD1TK1 | |
| SCHEMBL3446958 | 0.93 | POLB (0.60) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL8859644 | 0.93 | POLB (0.61) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL28543730 | 0.91 | POLB (0.59) | POLBPOLA1POLD1TK1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250369027-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | TWIST BIOSCIENCE CORP (US) | 2025-12-04 | — | — | US | claimed |
| CN-119677866-A | Substrate cleavage for nucleic acid synthesis | 特韦斯特生物科学公司 | 2025-03-21 | — | — | CN | claimed |
| EP-4504959-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | Twist Bioscience Corporation (US) | 2025-02-12 | — | — | EP | claimed |
| US-20240344057-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation | 2024-10-17 | — | — | US | claimed |
| WO-2023196499-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | Twist Bioscience Corporation (US) | 2023-10-12 | — | — | WO | claimed |
| EP-4229210-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation (US) | 2023-08-23 | — | — | EP | claimed |
| WO-2022086866-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation (US) | 2022-04-28 | — | — | WO | claimed |
| US-20260132223-A1 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | ANSA BIOTECHNOLOGIES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4731762-A2 | DE NOVO STEPWISE TEMPLATE-INDEPENDENT SYNTHESIS OF LONG POLYNUCLEOTIDES | Ansa Biotechnologies, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250369027-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | TWIST BIOSCIENCE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4594480-A2 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | Ansa Biotechnologies, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024073349-A9 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | ANSA BIOTECHNOLOGIES, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119677866-A | Substrate cleavage for nucleic acid synthesis | 特韦斯特生物科学公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4229210-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220145289-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation | 2022-05-12 | — | — | US | disclosed |
| WO-2022086866-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation (US) | 2022-04-28 | — | — | WO | disclosed |
| US-8133702-B2 | Engineered fluorescent dye labeled nucleotide analogs for DNA sequencing | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20120028248-A1 | ENGINEERED FLUORESCENT DYE LABELED NUCLEOTIDE ANALOGS FOR DNA SEQUENCING | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-7973146-B2 | Engineered fluorescent dye labeled nucleotide analogs for DNA sequencing | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090246791-A1 | ENGINEERED FLUORESCENT DYE LABELED NUCLEOTIDE ANALOGS FOR DNA SEQUENCING | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246791-A1 | ENGINEERED FLUORESCENT DYE LABELED NUCLEOTIDE ANALOGS FOR DNA SEQUENCING | POLM, POLN, POLB | POLB 3/4885POLA1 14/4885POLD1 30/4885 |
| US-20260132223-A1 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | POLN, PCNA, POLB | POLB 3/4885POLA1 22/4885POLD1 34/4885 |
| US-20120028248-A1 | ENGINEERED FLUORESCENT DYE LABELED NUCLEOTIDE ANALOGS FOR DNA SEQUENCING | POLN, POLM, RNGTT | POLB 5/4885POLA1 21/4885POLD1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.